INTRODUCTION {#s1}
============

Thyroid cancer (TC) is the most common endocrine malignancy in United States with rapidly rising incidence. The American Cancer Society estimates 56,850 new cases of thyroid cancer in 2017. Morphologically, the thyroid cancers are classified as papillary, follicular, medullary and anaplastic. Differentiated papillary (PTC) and follicular forms comprise 90-95% of thyroid cancers and are treatable, whereas anaplastic thyroid cancer (ATC) is the rarest but the most fatal and incurable form of the disease, with a median survival of 5 months \[[@R1]\]. ATC is an undifferentiated cancer arising presumably from pluripotent thyroid progenitor cells and accumulating genetic lesions. ATC is aneuploid with several chromosomal abnormalities and loss of heterozygosity. ATC can range from poorly differentiated TC characterized by high mitotic index to squamaous TC where its thyroid origin is difficult to ascertain.

For most ATCs, mutation of BRAF (v-raf murine sarcoma viral oncogene homolog B) or in rare cases, detection of RET/PTC and PAX8/PPAR fusions suggests thyroid origin of cells \[[@R2]--[@R4]\]. Presence of the tumor protein TP53 and β-catenin commonly found in ATCs but occasionally seen in poorly differentiated carcinoma also suggests tumor dedifferentiation \[[@R5]--[@R10]\]. ATC etiology is not completely understood; however several premises indicate that it originates from thyroid stem cells to manifest an undifferentiated, but aggressive phenotype \[[@R11], [@R12]\]. It is believed that both the papillary and follicular thyroid cancers result from a similar differentiation program coupled with the development of mutations most notably RET/PTC, RAS and BRAF for PTC and/or PAX8/PPARΎ \[[@R13]--[@R17]\]. However, genetic lesions are not uniformly distributed and no single or group of mutations define ATC \[[@R12], [@R13], [@R18]--[@R20]\]. The heterogeneity of tumor cell differentiation and the repertoire of genetic lesions (although TC has the least numbers of genetic lesions as compared to other TCs) makes difficult the task of developing a universal therapy with demonstrated clinical efficacy \[[@R21], [@R22]\].

There are several interactive open-access dbases of cancer transcriptomic signatures and even an Atlas of the Human Cancer Transcriptome \[[@R23]\] presenting favorable and unfavorable prognostic genes with associated Kaplan-Mayer surviving diagrams. In previous papers \[[@R24]--[@R28]\], we have analyzed the significance and utility of several potential TC biomarkers and therapeutic targets and their dependence on sex hormones \[[@R29]--[@R32]\]. However, being selected from the most frequently altered (as sequence or/and expression) genes in large population cohorts, the biomarkers appeared as less protected by the homeostatic mechanisms like low players in cell life. Therefore, restoration of the structure/expression of the altered biomarkers has most likely little therapeutic value. This explains why so far, no TC gene biomarker \[[@R33], [@R34]\] proved therapeutically efficient. Moreover, not only the biomarker(s) but thousands other genes are altered in TC, in (although partially overlapping) never repeatable combinations and nobody knows whether the neglected contributions of the other gene alterations are really negligible.

If cancer and normal cells are governed by distinct gene master regulators (GMRs) than "smart" manipulation of GMRs would selectively destroy the cancer nodules without much damage to the surrounding healthy tissue. The idea of master regulators has been around for almost four decades, most authors looking for transcription factors occupying the top of the regulatory hierarchy that determines cell fate and differentiation. Sophisticated algorithms using reverse engineering of transcriptional networks have been proposed and validated for use in therapeutic decision making \[[@R35]\]. KEGG (<http://www.genome.jp>), GenMapp (<http://genmapp.org>), IPA (<http://ingenuity.com>), DAVID (<http://david.abcc.ncifcrf.gov>) and other popular software have been developed to ensemble the biomarkers and other genes in functional pathways. Regardless of the method (Pearson correlation, Boolean, Bayesian, differential equations or just knowledge-based) to network the genes with respect to their co-regulation in different conditions \[[@R36], [@R37]\], such algorithms implicitly assumes ironclad functional pathways. This is a major weakness given the evident morphological and physiological changes during cancerization and in response to chemo-, radio and cell therapy. Although manually curated by genomic experts, the functional pathways constructed by these (actually) text miners are also "too" universal, lacking specificity with respect to race/strain, sex, age, and risk factors. Moreover, they are deterministic (unique network) in spite of the stochastic nature of the chemical reactions leading to an environmentally depending spectrum of possible "wirings" of the same subset of genes.

We consider as GMR a gene whose highly protected expression by the homeostatic mechanisms governs the phenotype by regulating the transcription of genes involved in major functional pathways through expression coordination. The high protection (indicating the critical importance for cell life) confines expression oscillations of GMRs in narrow intervals. Therefore, GMRs are rarely found spontaneously regulated and by consequence not selected as biomarkers. We estimate the protection of GMR from the reduced expression variability and its power to modulate a pathway from the Pearson correlation with expression oscillations of the pathway genes in biological replicas (obtained by splitting in four the malign and normal regions of the removed tumor).

Our approach, consistent with the Genomic Fabric Paradigm (GFP, \[[@R38], [@R39]\], does not provide novel biomarkers for TC diagnostic in ALL patients but a revolutionary way to cure the TC of the ACTUAL patient. The genomic fabric is defined as the transcriptome associated with the most interconnected and stably expressed network of genes responsible for a particular functional pathway. The fabric exhibits specificity with respect to race/strain, sex and sex hormones, age, tissue/cell type, and life style and environmental factors. It remodels during development, progression of a disease and in response to external stimuli and treatments.

Recently \[[@R40]\], we tested the hypothesis that *cancer and normal cells are governed by different GMRs* in the normal cortex and two primary tumor regions of a surgically removed clear cell renal cell carcinoma from a 74y old male. Here, we test again this hypothesis in a papillary cancer and cancer free surrounding tissue from the left thyroid lobectomy of a 33y old female. The efficacy of GMR targeting was checked by determining the transcriptomic effects of stable transfection of genes with different GCHs in the papillary BCPAP \[[@R41]\] and anaplastic 8505C \[[@R42]\] human TC cells that we used in previous studies \[[@R25], [@R27]--[@R29]\].

RESULTS {#s2}
=======

Experimental methods and raw and normalized gene expression data complying with the "Minimum Information about Microarray Experiments" (MIAME, \[[@R43]\]) were deposited in <https://www.ncbi.nlm.nih.gov/gds/> and are publically accessible as GSE97001, GSE97002, GSE97028, GSE97030, GSE97031 and GSE97427.

Cancer alters expression and coordination of numerous genes {#s2_1}
-----------------------------------------------------------

Compared to the normal tissue, expression of 5.1%% of the quantified unigenes was up-regulated and of 2.7% was down-regulated in the malignant region of the excised thyroid tumor. When comparison was extended to the papillary BCPAP cells, 17.10% of the genes were up-regulated and 15.53 down-regulated, while in the anaplastic 8505C cells, 17.09% of the genes were up- and 18.79% were down-regulated. Table [1](#T1){ref-type="table"} lists the fold-change (negative for down-regulation) and the p-value of the regulation, and Figure [1A](#F1){ref-type="fig"} the interconnection of the genes included in the KEGG[^1^](#FN1){ref-type="fn"} -determined pathway of thyroid cancer with respect to the surrounding unaffected tissue of thyroid.

###### Regulation of the genes included in the KEGG-determined functional pathway of thyroid cancer

  Gene      Systematic name   Description                                            FC                    p-val
  --------- ----------------- ------------------------------------------------------ --------------------- --------
  BAK1      NM_001188         BCL2-antagonist/killer 1                               1.05                  0.9125
  BAX       NM_138764         BCL2-associated X protein                              2.18                  0.0190
  BRAF      NM_004333         v-raf murine sarcoma viral oncogene homolog B          1.52                  0.3870
  CCDC6     NM_005436         coiled-coil domain containing 6                        -1.28                 0.5853
  CCND1     NM_053056         cyclin D1                                              2.90                  0.0223
  CDH1      NM_004360         cadherin 1, type 1, E-cadherin                         1.17                  0.8237
  CDKN1A    NM_078467         cyclin-dependent kinase inhibitor 1A                   2.65                  0.0205
  CTNNB1    NM_001904         catenin                                                2.59                  0.0191
  DDB2      NM_000107         damage-specific DNA binding protein 2, 48kDa           2.31                  0.0603
  GADD45A   NM_001924         growth arrest and DNA-damage-inducible, alpha          -1.52                 0.3406
  GADD45B   NM_015675         growth arrest and DNA-damage-inducible, beta           -2.07                 0.0895
  GADD45G   NM_006705         growth arrest and DNA-damage-inducible, gamma          -2.00                 0.0222
  HRAS      NM_005343         Harvey rat sarcoma viral oncogene homolog              1.80                  0.0254
  KRAS      NM_004985         Kirsten rat sarcoma viral oncogene homolog             2.84                  0.0208
  LEF1      NM_016269         lymphoid enhancer-binding factor 1                     1.91                  0.0323
  MAP2K1    NM_002755         mitogen-activated protein kinase kinase 1              1.71                  0.0150
  MAP2K2    NM_030662         mitogen-activated protein kinase kinase 2              1.35                  0.5240
  MAPK1     NM_138957         mitogen-activated protein kinase 1                     1.88                  0.0308
  MAPK3     NM_002746         mitogen-activated protein kinase 3                     1.28                  0.6278
  MYC       NM_002467         v-myc avian myelocytomatosis viral oncogene homolog    -1.46                 0.4439
  NCOA4     NM_001145260      nuclear receptor coactivator 4                         -1.27                 0.5110
  NRAS      NM_002524         neuroblastoma RAS viral                                -1.26                 0.6097
  NTRK1     NM_002529         neurotrophic tyrosine kinase, receptor, type 1         ***not available***   
  PAX8      NM_003466         paired box 8                                           -1.99                 0.0174
  POLK      NM_016218         polymerase                                             -1.10                 0.8021
  PPARG     NM_138711         peroxisome proliferator-activated receptor gamma       -5.00                 0.0911
  RET       NM_020630         ret proto-oncogene                                     1.10                  0.8589
  RXRA      NM_002957         retinoid X receptor, alpha                             -1.66                 0.2898
  RXRB      NM_021976         retinoid X receptor, beta                              -1.09                 0.8583
  RXRG      NR_033824         retinoid X receptor, gamma                             ***not available***   
  TCF7      NM_003202         transcription factor 7                                 4.26                  0.0724
  TCF7L1    NM_031283         transcription factor 7-like 1                          -4.08                 0.0492
  TCF7L2    NM_001198531      transcription factor 7-like 2                          -1.02                 0.9648
  TFG       NM_006070         TRK-fused gene                                         -1.28                 0.5636
  TP53      NM_001126118      tumor protein p53                                      1.37                  0.1237
  TPM3      NM_001043352      tropomyosin 3                                          1.34                  0.3639
  TPR       NM_003292         translocated promoter region, nuclear basket protein   2.51                  0.0196

Gene expression levels in the cancer nodule were compared with the corresponding values in the surrounding unaffected tissue of the profiled thyroid.Red/green/yellow background in the original tables the gene symbols had red/green/yellow background. Please add the background. For instance, the last gene symbol TPR should be in a red background of the gene symbol indicates up-/down-/no regulation, will white background indicates that the expression of the corresponding gene was not quantifiable in all 4 samples from the cancer nodule AND all 4 samples from the unaffected surrounding tissue. FC = fold-change (negative for down-regulation), p-val = p-value of the heteroscedastic *t*-test of the equality of the average expression level in the tumor side and in the surrounding normal tissue.

![Papillary cancer of the thyroid regulates numerous genes and remodel transcriptomic networks\
**(A)** Regulation of the KEGG-determined pathway of thyroid cancer. Red/green/yellow background of the gene symbol indicates up-/down/no regulation. GADD45G\|A\|B indicates the three growth arrest and DNA-damage-inducible genes: gamma, alpha and beta. **(B)** Percentages of up- and down regulated genes in various groups. APOPT = apoptosis, B-MARKS = biomarkers, CANCER = thyroid cancer, HORMONES = thyroid hormones, LI ncRNAs = long intergenic non-protein coding RNAs, TRF = transcription factors, ALL = the entire transcriptome. **(C)** Examples of genes synergistically (*DCPP2* = decapping mRNA 2), antagonistically (*CCNJ =* cyclin J) and independently (*PDCD1* = programmed cell death 1) expressed with H19 (= H19, imprinted maternally expressed transcript, long non-coding RNA). Numbers near gene symbols are Pearson pair-wise correlation coefficients between the (log~2~) expression levels of *H19* and linked gene. **(D)** Example of remodeling of the transcriptomic networks by which ncRNAs regulate apoptosis. Red/blue line indicates significant (p-val \< 0.05) synergism/antagonism between the linked gene and ncRNA. Numbers close to genes and ncRNAs' symbols are their hosting chromosomes (Chr).](oncotarget-09-2410-g001){#F1}

We found a significant overexpression of members of the *Ras* oncogene family *HRAS* and *KRAS* (known for their prominent roles in various types of cancer (e.g. \[[@R44], [@R45]\]. MAP2K1 (mitogen-activated kinase 1), part of the RAS/MAPK pathways, which informs the cell nucleus about the extracellular chemical environment was also up-regulated. Expression of *TP53* was not affected, indicating lack of ATC development \[[@R46], [@R47]\]. Figure [1B](#F1){ref-type="fig"} presents the percentages of up- and down regulated genes in several well-defined groups of genes. Interestingly, out of the investigated groups of genes, the biomarkers selected from \[[@R48]\] formed the second most regulated group (after the thyroid cancer genes), confirming their value for TC diagnosis. In contrast, the transcription factors (TRF) formed the least regulated group (0.0% up and 2.3% down). With 16.5% up and 9.6% down-regulated genes (listed in Table [2](#T2){ref-type="table"}) apoptosis is also a major pathway with substantial alteration in thyroid cancer.

###### Significantly regulated apoptosis genes in the cancer nodule with respect to the surrounding unaffected tissue of the profiled thyroid

  Gene        Systematic name   Description                                                                                     FC      p-val
  ----------- ----------------- ----------------------------------------------------------------------------------------------- ------- --------
  BAX         NM_138764         BCL2-associated X protein                                                                       2.18    0.0190
  BBC3        NM_014417         BCL2 binding component 3                                                                        2.80    0.0073
  BCL2        NM_000633         B-cell CLL/lymphoma 2                                                                           -3.34   0.0087
  BCL2L11     NM_138621         BCL2-like 11                                                                                    -3.25   0.0073
  BID         NM_197966         BH3 interacting domain death agonist                                                            5.77    0.0317
  BIRC5       NM_001012271      baculoviral IAP repeat containing 5                                                             4.14    0.0090
  CASP3       NM_004346         caspase 3, apoptosis-related cysteine peptidase                                                 4.01    0.0379
  CTSH        NM_004390         cathepsin H                                                                                     6.39    0.0044
  CTSK        NM_000396         cathepsin K                                                                                     -1.88   0.0126
  CTSV        NM_001333         cathepsin V                                                                                     -1.80   0.0282
  CYCS        NM_018947         cytochrome c, somatic                                                                           -2.14   0.0182
  DAB2IP      NM_032552         DAB2 interacting protein                                                                        2.88    0.0099
  FAS         NM_000043         Fas cell surface death receptor                                                                 2.79    0.0075
  FOS         NM_005252         FBJ murine osteosarcoma viral oncogene homolog                                                  -2.15   0.0140
  GADD45B     NM_015675         growth arrest and DNA-damage-inducible, beta                                                    -2.07   0.0089
  GADD45G     NM_006705         growth arrest and DNA-damage-inducible, gamma                                                   -2.00   0.0222
  GZMB        NM_004131         granzyme B                                                                                      -2.27   0.0081
  HRAS        NM_005343         Harvey rat sarcoma viral oncogene homolog                                                       1.80    0.0254
  HRK         ENST00000257572   harakiri, BCL2 interacting protein                                                              3.01    0.0065
  ITPR2       NM_002223         inositol 1,4,5-trisphosphate receptor, type 2                                                   3.28    0.0079
  JUN         NM_002228         jun proto-oncogene                                                                              -3.38   0.0055
  KRAS        NM_004985         Kirsten rat sarcoma viral oncogene homolog                                                      2.84    0.0208
  LMNA        NM_005572         lamin A/C                                                                                       2.92    0.0053
  MAP2K1      NM_002755         mitogen-activated protein kinase kinase 1                                                       1.71    0.0150
  MAPK1       NM_138957         mitogen-activated protein kinase 1                                                              1.88    0.0308
  NFKB1       NM_003998         nuclear factor of kappa light polypeptide gene enhancer in B-cells 1                            2.15    0.0069
  PARP1       NM_001618         poly (ADP-ribose) polymerase 1                                                                  2.50    0.0078
  TNFRSF10B   NM_003842         tumor necrosis factor receptor superfamily, member 10b                                          1.84    0.0080
  TNFRSF10C   NM_003841         tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain   7.14    0.0242
  TNFSF10     NM_003810         tumor necrosis factor (ligand) superfamily, member 10                                           -4.11   0.0064

Red/green background of the gene symbol indicates significant up-/down regulation. FC = fold-change (negative for down-regulation), p-val = p-value of the heteroscedastic *t*-test of the equality of the average expression level in the tumor side and in the surrounding normal tissue.

We found also substantial remodeling of the transcriptomic networks by which the long intergenic non-protein coding RNAs (LI ncRNA) modulate major functional pathways through expression coordination (principle in Figure [1C](#F1){ref-type="fig"}) with pathway genes. Thus, Figure [1D](#F1){ref-type="fig"} presents the remodeling of part of the transcriptomic networks that LI ncRNAs form with apoptotic genes (coordination values in Table [3](#T3){ref-type="table"}). Notably, some synergistically expressed gene pairs in normal tissue became independently expressed in cancer (*ANKRD36BP2-BCL2*, *PMS2L2-TNFRSF10D, PMS2L2-TNFRSF1A*) or an independently expressed pair (*HCG11-PPP3CB*) in normal became antagonistically expressed in cancer. *H19* strong antagonism with expression of apoptotic genes in normal tissue is practically cancelled in cancer, confirming its important role in cancer proliferation revealed by several authors \[[@R49]\]. Our coordination analysis revealed that LI ncRNAs can modulate expression of genes located not only on the same but also on other chromosomes. For instance, in the normal tissue, H19 from Chr 11 antagonizes apoptosis genes from Chr 1 (*AKT3, CAPN2, DFFA, DFFB, PIK3CD*), Chr 3 (*PRKAR2A*), Chr 4 (*CASP6, PPP3CA*), Chr 6 (*RIPK1*), Chr 7 (*PRKAR1B*). Chr 8 (*IKBKB, PPP3CC, TNFRSF10B TNFRSF10D*), Chr 9 (*ENDOG*), Chr 10 (*CASP7, CHUCK, FAS*), Chr 11 (*BIRC2, CAPN1, FADD*), Chr 12 (*TNFRSF1A*). Chr 14 (*AKT1, NFKBIA*), Chr 17 (*MAPK3K14, PRKAR1A*), Chr 19 (*BAX, PIK3R2*), Chr 20 (BCL2L1) and Chr X (*XIAP*). In the malign region, the (p \< 0.05) significant expression coordination of *H19* is limited to a single apoptosis gene, *BCL2* (Chr 18) that, interestingly, is not coordinately expressed with *H19* in normal tissue. [Supplementary Table 1](#SD1){ref-type="supplementary-material"} lists all regulated genes in the cancer nodule with respect to the surrounding normal tissue.

###### Expression coordination values between LI ncRNA and apoptosis genes in normal and malign part of the tumor

  Normal      ANKRD36BP2   FAM86B3P   H19      HCG11    PMS2L2   Malign      ANKRD36BP2   FAM86B3P   H19      HCG11    PMS2L2
  ----------- ------------ ---------- -------- -------- -------- ----------- ------------ ---------- -------- -------- --------
  AKT1        0.680        0.978      -0.908   0.649    0.929    AKT1        0.984        0.749      0.144    0.964    -0.173
  AKT2        0.940        0.693      -0.519   0.948    0.591    AKT2        0.858        0.999      0.205    0.834    -0.180
  AKT3        0.361        0.983      -0.999   0.313    0.986    AKT3        0.672        0.357      -0.446   0.590    0.399
  ATM         0.786        0.934      -0.835   0.756    0.858    ATM         0.953        0.644      0.356    0.967    -0.394
  BAD         0.982        0.610      -0.421   0.986    0.483    BAD         0.911        0.952      0.451    0.923    -0.438
  BAX         0.599        0.994      -0.945   0.567    0.963    BAX         0.951        0.950      0.122    0.918    -0.118
  BCL2        0.921        0.793      -0.652   0.888    0.667    BCL2        0.008        -0.120     -0.939   -0.117   0.913
  BCL2L1      0.574        0.952      -0.922   0.509    0.888    BCL2L1      0.794        0.371      -0.074   0.763    0.015
  BID         0.362        0.958      -0.979   0.297    0.940    BID         0.993        0.886      0.314    0.989    -0.324
  BIRC2       0.099        0.892      -0.952   0.075    0.962    BIRC2       0.942        0.708      0.533    0.978    -0.559
  BIRC3       0.981        0.670      -0.494   0.968    0.534    BIRC3       0.952        0.810      0.538    0.983    -0.551
  CAPN1       0.195        0.938      -0.991   0.144    0.966    CAPN1       0.808        0.359      0.099    0.801    -0.160
  CAPN10      0.871        0.862      -0.730   0.855    0.772    CAPN10      0.994        0.780      0.195    0.979    -0.221
  CAPN2       0.332        0.979      -1.000   0.287    0.989    CAPN2       0.920        0.978      0.143    0.888    -0.130
  CASP10      0.302        0.809      -0.846   0.210    0.757    CASP10      0.949        0.952      0.122    0.916    -0.118
  CASP3       0.806        0.922      -0.816   0.778    0.842    CASP3       0.963        0.868      0.482    0.984    -0.488
  CASP6       0.547        0.994      -0.955   0.519    0.978    CASP6       0.932        0.593      0.122    0.917    -0.167
  CASP7       0.091        0.899      -0.968   0.055    0.960    CASP7       0.968        0.826      0.490    0.991    -0.503
  CASP9       -0.073       0.727      -0.799   -0.065   0.846    CASP9       0.986        0.837      0.410    0.998    -0.425
  CFLAR       0.880        0.843      -0.718   0.841    0.726    CFLAR       0.980        0.712      0.283    0.980    -0.316
  CHUK        0.327        0.976      -0.992   0.293    0.999    CHUK        0.988        0.753      0.320    0.992    -0.348
  CYCS        0.059        0.773      -0.814   0.073    0.875    CYCS        0.793        0.655      0.792    0.868    -0.802
  DFFA        0.648        0.954      -0.903   0.590    0.881    DFFA        0.763        0.349      -0.167   0.720    0.108
  DFFB        0.503        0.916      -0.905   0.428    0.851    DFFB        0.981        0.720      0.181    0.967    -0.214
  ENDOG       0.485        0.995      -0.973   0.455    0.991    ENDOG       0.981        0.887      0.399    0.989    -0.406
  FADD        0.691        0.975      -0.903   0.659    0.922    FADD        0.988        0.745      0.207    0.976    -0.237
  FAS         0.418        0.993      -0.994   0.373    0.987    FAS         0.871        0.742      0.697    0.928    -0.707
  IKBKB       0.089        0.873      -0.930   0.073    0.952    IKBKB       0.930        0.899      0.523    0.954    -0.520
  IKBKG       0.377        0.973      -0.989   0.319    0.960    IKBKG       0.999        0.814      0.251    0.990    -0.272
  IL1B        0.602        0.918      -0.881   0.531    0.838    IL1B        0.810        0.900      0.618    0.848    -0.597
  IL1RAP      -0.476       0.427      -0.571   -0.466   0.595    IL1RAP      0.725        0.316      -0.239   0.674    0.181
  IRAK1       0.683        0.919      -0.860   0.620    0.829    IRAK1       0.857        0.464      -0.003   0.831    -0.051
  MAP3K14     0.342        0.970      -0.994   0.285    0.967    MAP3K14     0.993        0.767      0.254    0.987    -0.281
  MYD88       0.865        0.856      -0.722   0.855    0.772    MYD88       0.982        0.868      0.415    0.993    -0.425
  NFKB1       0.372        0.915      -0.899   0.374    0.956    NFKB1       0.647        0.870      0.620    0.687    -0.580
  NFKBIA      -0.048       0.830      -0.925   -0.083   0.912    NFKBIA      0.665        0.748      0.808    0.737    -0.787
  PIK3CA      0.957        0.544      -0.348   0.977    0.431    PIK3CA      0.753        0.283      0.018    0.739    -0.083
  PIK3CB      0.706        0.866      -0.760   0.718    0.839    PIK3CB      0.723        0.226      0.206    0.738    -0.273
  PIK3CD      0.566        0.998      -0.960   0.529    0.970    PIK3CD      0.983        0.769      0.403    0.997    -0.427
  PIK3R1      0.423        0.907      -0.875   0.429    0.940    PIK3R1      0.893        0.505      0.311    0.908    -0.361
  PIK3R2      0.328        0.974      -0.998   0.276    0.978    PIK3R2      0.876        0.549      -0.110   0.831    0.065
  PPP3CA      0.106        0.872      -0.922   0.094    0.950    PPP3CA      0.788        0.329      0.077    0.779    -0.140
  PPP3CB      0.049        0.829      -0.886   0.044    0.921    PPP3CB      0.880        0.579      0.592    0.930    -0.627
  PPP3CC      0.512        1.000      -0.977   0.470    0.978    PPP3CC      0.949        0.621      0.232    0.947    -0.274
  PRKACA      0.912        0.778      -0.641   0.872    0.644    PRKACA      0.749        0.316      -0.143   0.710    0.082
  PRKACB      0.649        0.764      -0.709   0.566    0.641    PRKACB      0.680        0.238      -0.227   0.635    0.163
  PRKAR1A     0.109        0.865      -0.913   0.100    0.946    PRKAR1A     0.935        0.671      0.520    0.971    -0.550
  PRKAR1B     0.491        0.994      -0.980   0.441    0.968    PRKAR1B     0.984        0.733      0.188    0.970    -0.219
  PRKAR2A     0.442        0.993      -0.981   0.411    0.996    PRKAR2A     0.982        0.771      0.408    0.997    -0.432
  PRKAR2B     0.450        0.856      -0.858   0.364    0.785    PRKAR2B     0.968        0.672      0.224    0.962    -0.262
  RELA        -0.152       0.750      -0.876   -0.213   0.818    RELA        0.805        0.382      -0.050   0.776    -0.009
  RIPK1       0.433        0.994      -0.992   0.387    0.984    RIPK1       0.989        0.792      0.126    0.964    -0.150
  TNFRSF10B   0.302        0.945      -0.956   0.287    0.988    TNFRSF10B   0.725        0.782      0.775    0.791    -0.758
  TNFRSF10D   0.568        0.994      -0.952   0.539    0.973    TNFRSF10D   0.935        0.896      -0.038   0.882    0.036
  TNFRSF1A    0.562        0.984      -0.954   0.508    0.937    TNFRSF1A    0.764        0.317      -0.063   0.737    0.001
  TRAF2       -0.186       0.737      -0.867   -0.241   0.817    TRAF2       0.927        0.676      -0.079   0.880    0.045
  XIAP        0.409        0.990      -0.995   0.361    0.984    XIAP        0.505        0.228      -0.630   0.405    0.587

Red/blue/yellow background of the coordination value indicates that the paired genes were significantly (p-val \< 0.05) synergistically/antagonistically/ independently expressed in the indicated region. Note the differences between the two regions.

Cancer and normal cells have different gene hierarchies in the thyroid {#s2_2}
----------------------------------------------------------------------

Like our previous finding in a case of clear cell renal cell carcinoma \[[@R40]\] the microarray experiment on the left thyroid lobectomy proved existence of genes with large GCH differences between the cancer and the normal part of the tumor. Figure [2](#F2){ref-type="fig"} presents the gene commanding heights (GCH) in normal and malign regions of the analyzed thyroid tumor for several TC biomarkers, oncogenes, apoptosis genes and ncRNAs. Note that no biomarker has high GCH, explaining why none of them proved therapeutically efficient for TC. However, with GCH = 26.14 in the malign part and 1.41 (18.5x smaller) in the normal tissue, the 2.71x significantly up-regulated member of the RAS oncogene family *RAB15* may be therapeutically actionable for this person as reported for other cancer cases (e.g. \[[@R50]\]).

![Gene commanding height (GCH) of selected TC biomarkers **(A, B)** oncogenes (B, C) apoptosis genes **(D)** and non-coding RNAs **(E, F)** in the normal and malign part of the surgically removed TC tumor. Note the differences between the GCH scores in the two regions.](oncotarget-09-2410-g002){#F2}

Anaplastic and papillary TC phenotypes have major differences in cell-cycle pathway and gene networking {#s2_3}
-------------------------------------------------------------------------------------------------------

The transcriptomic profiles of the anaplastic (8505C) and papillary (BCPAP) TC cell lines were largely different, with the largest differences (61% = 45% up- and 16% down) in the expression of cell-cycle pathway genes (Figure [3A](#F3){ref-type="fig"}). This finding explains the accelerated progression to the undifferentiated form of the TC in 8505C cells \[[@R51]\]. Significant expression differences were noticed in both DNA replication (S phase) and mitosis (M phase) phases of the mitotic cell cycle progression as well as in the temporal gaps known as G1 and G2 phases. Such differences between the two TC cell lines justify some of the therapeutic approaches of the ATC. Thus, overexpression of the key regulatory cyclin-dependent kinase *CDK1* explains the choice of dinaciclib, a cyclin-dependent kinase inhibitor \[[@R52]\], while overexpression of the proto-oncogene *MYC* justifies the use of MYC potent inhibitor JQ1 \[[@R53]\]. *CDK6* is overexpressed and *CDK4* under-expressed, while *CDK2* and *CDK7* were similarly expressed in the two TC cell lines. All mini-chromosome maintenance genes (*MCM2, MCM3, MCM4, MCM5, MCM6, MCM7*), required to initiate eukaryotic DNA replication, were overexpressed in the 8505C cells, confirming previous reports (e.g. \[[@R54]\]) on other human ATC cell lines. Also overexpressed are three members of the origin recognition complex (*ORC4, ORC5, ORC6*) that were also previously linked to cancer development (e.g. \[[@R55]\]).

![Major differences between anaplastic 8505C and papillary BCPAP TC cells include expression of cell-cycle pathway genes **(A)** and transcriptomic networks by which *CIC* (= capicua transcriptional repressor) coordinates expression of apoptotic genes **(B--C)**. In B and C a red/blue line indicates that *CIC* and the other gene are (p-val \< 0.1) synergistically/antagonistically expressed. In order to visualize the strength of the expression coordination, the length of the line is proportional to ρ^3^ (ρ = Pearson pair-wise correlation coefficient). Thus, longer distances to *CIC* (as for *PRKAR1B, IRAK2* and *CYCS* in the 8505C network) indicate stronger expression coordination and by consequence stronger downstream influence. Note the differences between the two networks.](oncotarget-09-2410-g003){#F3}

The transcriptomes of the two phenotypes also differ in the way the genes are networked to accomplish various biological processes. For instance, Figure [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"} present the apoptosis genes that are significantly (p \< 0.05) coordinately expressed with *CIC* (= capicua transcriptional repressor) a gene related to the various forms of cancer (e.g.: \[[@R56], [@R57]\]. Of note is that *CIC* coordinates the expression of many more apoptosis genes in the anaplastic phenotype and that only synergism with *IL1A, PRKACA* and *PRKAR1A* is common to both phenotypes.

Predictive value of GCH score: expression manipulation of a gene has larger effects on cells it commands {#s2_4}
--------------------------------------------------------------------------------------------------------

We determined and compared the GCH scores of individual genes in the BCPAP and 8505C cell lines before any transfection (partially illustrated in Figure [4A](#F4){ref-type="fig"}). *DDX10, NEMP1, PANK2* and *UBALD1* were selected because of their availability (through Albert Einstein College of Medicine Genomics Facility), significantly different GCH-scores but close expression levels (AVE) and low coefficient of variation (CV) in the two cell lines (Figure [4B](#F4){ref-type="fig"}). The characteristics of the clones chosen to be stably transfected (one at a time) into the two types of cells are presented in Figure [4C](#F4){ref-type="fig"}. The microarray experiment validated (p-value = 0.000152) our hypothesis that manipulation of a gene\'s expression induced larger transcriptomic alterations in the cells where it has larger GCH (Figure [4D-4G](#F4){ref-type="fig"}). There is a perfect positive Spearman rank correlation between the (% regulated in BCPAP, % regulated in 8505C) and (GCH in BCPAP, GCH in 8505C) for all four transfected genes. Moreover, the strong positive Pearson product-momentum correlation with the percentage of regulated genes (Figure [4H](#F4){ref-type="fig"}) for each cell line validated the predictive value of GCH score.

![Validation of the gene commanding height (GCH) predictive value\
**(A)** Examples of genes (including known TC biomarkers) with large GCH differences in the two cell lines. **(B)** Average expression level (AVE), coefficient of variation (CV) and GCH of the selected genes in the two cell lines before any transfection. X = expression ratio, CUT = absolute fold-change cut-off for significantly differentially expressed genes, P-VAL = p-value of the differential expression. **(C)** Characteristics of the transfected clones. In all transfections, we used the same lentiviral vector pLX304. **(D-G)** GCH vs % regulated genes for each transfection experiment. Note that always, higher GCH is associated with larger percentage of regulated genes. **(H)** GCH increases with GCH in each cell type. Strong positive Pearson product-momentum correlations (r = 0.914 for BCPAP and r = 0.873 for 8505C cells) were found between the GCH scores and the percentage of significantly regulated genes in both cell lines.](oncotarget-09-2410-g004){#F4}

DISCUSSION {#s3}
==========

The main methodological contribution of our report is the introduction and validation of the Gene Commanding Height (GCH) as a new measure of how influential the expression of a gene is for the phenotypic expression of a cell. With this measure one can establish the gene hierarchy and identify the Gene Master Regulators (GMRs) of cancer nodules and unaffected surrounding tissue. Thus, GCH analysis opens a novel cancer gene-therapy avenue by selecting the targets with high differences in favor of the malign region from the affected tissue.

Owing to the cancer dependence on race, sex, age, genetic heritage, medical history, environmental and life-style associated risk factors, each patient most likely has a distinct and dynamic GMR-hierarchy. Therefore, an efficient gene-therapy should identify the targets separately for each individual. Manipulation of a GMR could *complement* current treatment options by making cancer cells more vulnerable and normal ones more resistant to chemo-/radiation therapy. It could also be used *post-surgical* removal of the tumor to reduce the probability of cancer recurrence.

GMRs are not biomarkers because biomarkers are the most alterable while GMRs are the most protected genes. GMRs are not selected as the most co-regulated with other genes in cancer vs. normal phenotypes because gene networks remodel in cancer and co-regulation does not necessarily mean gene interaction. Instead, GMRs are the most coordinately (synergistically or antagonistically) expressed with other genes in one phenotype at a time, dictating the transcriptomic stoichiometry \[[@R58]\] of gene networks.

In summary, we verified that cancer nodules and surrounding normal tissue are governed by different GMRs, and that manipulating the expression of a gene has larger effects on cells in which it has larger GCH.

MATERIALS AND METHODS {#s4}
=====================

Patient sample {#s4_1}
--------------

Four (2 -- 6 mm^3^) samples were dissected from a frozen unilateral, single, 32.0 mm papillary carcinoma, pathological stage pT3NOMx (<http://emedicine.medscape.com/article/2006643-overview>) collected in 2010 from a 33y old woman. Four small pieces from the negative for malignancy resection margins of the same tumor were used as control. The study was approved by New York Medical College and Westchester Medical Center (WMC) Committees for Protection of Human Subjects, commonly known as Institutional Review Boards (IRBs) by L-11,606 ("Comprehensive molecular analysis of thyroid cancer: diagnosis, predictors of progression and targets for directed therapy", PI RK Tiwari) and L-11,376 ("Quantifying cancer-associated remodeling of key genomic fabrics", PI. DA Iacobas). The approval granted access to frozen cancer specimens from the WMC Pathology Archives and depersonalized pathology reports, waiving patient\'s informed consent. Although the four samples dissected from each (malignant and malignant-free) region were chosen to be as homogeneous as possible cells of different phenotypes were not completely eliminated.

Cell lines {#s4_2}
----------

The predictive value of the GCH score was tested in papillary thyroid cancer cell line BCPAP and anaplastic thyroid cancer line 8505C, purchased from DSMZ in Braunschweig, Germany. Cell lines were cultured in Rosswell Park Memorial Institute (RPMI)-1640 supplemented with 10% fetal bovine serum (FBS), penicillin 10,000 IU/mL, streptomycin 10 mg/mL, and 2 mM L-glutamine. Validation of the cell lines was performed by the Genomics Core of the Albert Einstein College of Medicine (AECOM) of Yeshiva University (<http://www.einstein.yu.edu/research/shared-facilities/cores/46/genomics/>).

Gene transfection {#s4_3}
-----------------

The stable transfection was performed using plasmids in ORF lentiviral plX304 vector produced by the AECOM shRNA Core Facility with the characteristics indicated in Figure [4C](#F4){ref-type="fig"}.

Microarrays {#s4_4}
-----------

We used our standard protocol \[[@R59]\] for extraction the total RNA, reverse transcription and fluorescent labeling, and hybridization with Agilent (here human) 4×44k two-color gene expression microarrays in the "multiple-yellow" design. Four biological replicas (cell culture dishes or tissue samples) were profiled from each phenotype/cell type subjected to each condition.

Data analysis {#s4_5}
-------------

A gene was considered as differentially expressed between two types of samples if the absolute expression fold-change exceeded the combined effect of microarray noise and biological variability and the p-value of the means' equality was below 0.05. All genes were assigned to functional pathways using Kyoto Encyclopedia of Genes and Genomes (<http://www.genome.jp/kegg/pathway.html>).

In previous papers (e.g.: \[[@R38], [@R60], [@R61]\]) we have used the Relative Expression Variability (REV = median of the Bonferroni-corrected chi-square interval estimate of the coefficient of variation) as a statistical estimate of the expression variability of one gene among biological replicas. Expression of individual genes depends on local conditions that, although similar, are not identical among biological replicas. We assume that expression of key genes is kept by the cellular homeostatic mechanisms within narrow intervals while that of nonkey genes is less restrained to readily adapt to environmental changes. REV may shift in pathological conditions, suggesting that control mechanisms are also affected. The expression variability allows computing the Pearson product-momentum correlation coefficient between the expression levels of any two genes in the same condition. Using the coordination analysis, we determined the transcriptomic networks (that may cross cell boundaries as shown in \[[@R62]\])

Gene commanding height {#s4_6}
----------------------

Gene Commanding Height (GCH) in sample α (= benign, malign, BCPAP, 8505C) was computed for each protein-coding and non-coding transcript in each of the four conditions as a combined measure of the gene expression stability and coordination with each other gene:
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SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================

modified from map05216, Kanehisa Laboratories, <http://www.kegg.jp>
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